There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV – Research Report), Teladoc (TDOC – Research Report) and Gilead Sciences (GILD – Research Report) with bullish sentiments.
Roivant Sciences (ROIV)
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Roivant Sciences today and set a price target of $20.00. The company’s shares closed last Thursday at $10.88.
According to TipRanks.com, Bratzel is a 2-star analyst with an average return of
Roivant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $17.43, which is a 61.7% upside from current levels. In a report issued on April 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
Teladoc (TDOC)
In a report released today, Jessica Tassan from Piper Sandler maintained a Buy rating on Teladoc, with a price target of $25.00. The company’s shares closed last Thursday at $13.33, close to its 52-week low of $12.86.
According to TipRanks.com, Tassan is a 1-star analyst with an average return of
Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $19.13, implying a 42.3% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $18.00 price target.
Gilead Sciences (GILD)
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences, with a price target of $95.00. The company’s shares closed last Thursday at $65.27, close to its 52-week low of $65.09.
According to TipRanks.com, Catanzaro is a 4-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $84.21, which is a 24.8% upside from current levels. In a report issued on April 11, J.P. Morgan also maintained a Buy rating on the stock with a $95.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ROIV:
- Greenlight took long positions in HP, Penn Entertainment, Roivant Sciences in Q1
- Greenlight bought ‘small long position’ in Roivant during Q1
- Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
- Moderna could owe $1B-$3B in royalties, says Jefferies
- Roivant, Arbutus higher after ruling on COVID patent order
